An Open-label, Randomised, No-treatment-controlled, Single-centre, Phase I, Crossover Study Evaluating the Suppression of Plasma Cortisol from Symbicort  budesonide/formoterol) pMDI 80/2.25 ?g, 8 Actuations bid, versus Symbicort Turbuhaler 160/4.5 ?g, 4 Inhalations bid, in Healthy Subjects

Study identifier:D5897C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Randomised, No-treatment-controlled, Single-centre, Phase I, Crossover Study Evaluating the Suppression of Plasma Cortisol from Symbicort  budesonide/formoterol) pMDI 80/2.25 ?g, 8 Actuations bid, versus Symbicort Turbuhaler 160/4.5 ?g, 4 Inhalations bid, in Healthy Subjects

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Dec 2007
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria